

**TERMINAL DISCLAIMER TO OBVIATE A
DOUBLE PATENTING REJECTION
OVER A PRIOR PATENT**


Docket Number:
P0633.70014US01

In re Application of: Leonid A. Kozhemyakin, et al.
Application No. 10/747,855
Confirmation No. 2748
Filed: December 29, 2003
For: METHODS FOR PRODUCTION OF THE OXIDIZED
GLUTATHIONE COMPOSITE WITH CIS-
DIAMMINEDICHLOROPLATINUM AND PHARMACEUTICAL
COMPOSITIONS BASED THEREOF REGULATING
METABOLISM, PROLIFERATION, DIFFERENTIATION AND
APOPTOTIC MECHANISMS FOR NORMAL AND
TRANSFORMED CELLS

The owner*, Novelos Therapeutics, Inc., of 100% percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §154 to §156 and §173 as presently shortened by any terminal disclaimer, of prior Patent No. 6,312,734. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §154 to §156 and §173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. §1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

The undersigned is an attorney or agent of record.



August 7, 2005

Signature

Date

Timothy J. Oyer, Ph.D., Reg. No. 36,628

Typed or Printed Name

Terminal disclaimer fee under 37 CFR 1.20(d) included.

*Statement under 37 CFR. 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP §324.

927214

08/23/2005 MBIZUNES 00000078 10747855

03 FC:2814

65.00 OP